- $702.49m
- $193.99m
- €535.18m
- 80
- 96
- 55
- 91
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.89 | ||
| Price to Tang. Book | 0.92 | ||
| Price to Free Cashflow | 7.39 | ||
| Price to Sales | 1.15 | ||
| EV to EBITDA | 0.85 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 24.32% | ||
| Return on Equity | 26.73% | ||
| Operating Margin | 33.2% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 48.87 | 102.99 | 67.42 | 53.76 | 535.18 | 77.3 | 94.69 | 98.39% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
CureVac NV, formerly CureVac AG, is a Germany-based clinical-stage biopharmaceutical company. The Company develops transformative medicines based on messenger ribonucleic acid, or mRNA. The Company's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The Company's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).
Directors
- Baron Stephenne CSU (71)
- Franz-Werner Haas CEO (52)
- Friedrich von Bohlen und Halbach VSU (59)
- Pierre Kemula CFO (47)
- Mariola Fotin-Mleczek CTO (54)
- Igor Splawski CSO (53)
- Antony Blac MGB (53)
- Senta Gnad-Vogt MGB (49)
- Florian Von der Mulbe MGB (48)
- Hans Tanner IND (71)
- Craig Tooman IND (55)
- Viola Bronsema SUB (58)
- Ralf Clemens SUB (68)
- Mathias Hothum SUB (54)
- Timothy Wright SUB (65)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 7th, 2020
- Public Since
- August 14th, 2020
- No. of Employees
- 825
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 225,155,874
- Address
- Friedrich-Miescher-Str. 15, TUEBINGEN, 72076
- Web
- https://www.curevac.com/
- Phone
- +49 707198830
- Contact
- Sarah Fakih
- Auditors
- KPMG AG Wirtschaftsprufungsgesellschaft
Upcoming Events for CVAC
CureVac NV Annual Shareholders Meeting
Q2 2025 CureVac NV Earnings Release
Similar to CVAC
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
What is the CureVac NV share price?
As of Today at 20:08 UTC, shares in CureVac NV are trading at $3.12. This share price information is delayed by 15 minutes.
How has the CureVac NV share price performed this year?
Shares in CureVac NV last closed at $3.12 and the price had moved by +21.4% over the past 365 days. In terms of relative price strength the CureVac NV share price has outperformed the S&P500 Index by +14.15% over the past year.
What are the analyst and broker recommendations for CureVac NV?
The overall consensus recommendation for CureVac NV is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the CureVac NV dividend yield?
CureVac NV does not currently pay a dividend.
Does CureVac NV pay a dividend?
CureVac NV does not currently pay a dividend.
When does CureVac NV next pay dividends?
CureVac NV does not currently pay a dividend.
How do I buy CureVac NV shares?
To buy shares in CureVac NV you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of CureVac NV?
As of the previous close price of $3.12, shares in CureVac NV had a market capitalisation of $702.49m.
Where are CureVac NV shares listed?
Here are the trading details for CureVac NV:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: CVAC
What kind of share is CureVac NV?
Based on an overall assessment of its quality, value and momentum CureVac NV is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a CureVac NV share price forecast for 2025?
The analyst consensus target price for shares in CureVac NV is $6.84. That is 119.25% above the last closing price of $3.12.
Analysts covering CureVac NV currently have a consensus Earnings Per Share (EPS) forecast of -€0.52 for the next financial year.
Find out moreWhat is the trend in the CureVac NV share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like CureVac NV. Over the past six months, its share price has outperformed the S&P500 Index by +23.48%.
As of the last closing price of $3.12, shares in CureVac NV were trading -2.35% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the CureVac NV PE Ratio?
The CureVac NV PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.12.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of CureVac NV?
CureVac NV's management team is headed by:
- Baron Stephenne - CSU
- Franz-Werner Haas - CEO
- Friedrich von Bohlen und Halbach - VSU
- Pierre Kemula - CFO
- Mariola Fotin-Mleczek - CTO
- Igor Splawski - CSO
- Antony Blac - MGB
- Senta Gnad-Vogt - MGB
- Florian Von der Mulbe - MGB
- Hans Tanner - IND
- Craig Tooman - IND
- Viola Bronsema - SUB
- Ralf Clemens - SUB
- Mathias Hothum - SUB
- Timothy Wright - SUB